BTIG reiterates Monopar Therapeutics stock rating on NDA progress

BTIG reiterated a Buy rating and $133 price target for Monopar Therapeutics (MNPR), citing progress in its NDA submission for ALXN1840. The stock trades at $68.05, with a consensus price target range of $119-$145. Management extended its cash runway guidance to Q1 2028 and presented positive trial data. Analysts have mixed views on the stock's valuation.

Original reporting
Published Nov 12, 2026, 5:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 5:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MNPR
Bullish
medium confidence
Mentioned
$MNPR
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MNPRBullishLow
01

Why it matters

Analyst rating and target adjustments provide modest sentiment cues but no new corporate catalyst.

02

Market read

Minor relevance; primarily an analyst opinion piece.

03

What to watch

Potential competition and the need for FDA approval could temper upside.

Relevance 4/10Novelty 2/10Timing: none

Background

The article repeats analyst coverage of Monopar Therapeutics, focusing on rating and target changes.

Company-level read

Ticker impact

$MNPRBullishMedium confidence
Context

BTIG reiterated a Buy rating and raised the price target to $133, citing progress on the rolling NDA for ALXN1840 and extended cash runway.

Expected impact

likely upward pressure as investors price in the higher target and NDA progress

Evidence & confidence

The rating and target raise are fresh analyst actions, but no new material corporate event; impact is limited to sentiment.

Market effects

Limited; reflects broader biotech analyst sentiment on NDA progress.

None

Low

Counterpoint

The price target may be overly optimistic given the delayed NDA timeline.

Key entities

  • Monopar Therapeutics

    Biotech firm developing ALXN1840.

  • BTIG

    Issued the reiterated Buy rating and price target.

Related articles

$MNPRMed

Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, November 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative t

$MNPRMedAI 8/10

Monopar presents Wilson disease trial data at liver conference

Monopar Therapeutics (MNPR) presented Phase 3 FoCus trial data for Wilson disease at a liver conference. Key findings include high rates of cirrhosis, neurologic, and psychiatric symptoms among patients. ALXN1840, its investigational therapy, showed positive long-term data. The trial is the largest randomized controlled study in Wilson disease.

$MNPRMedAI 8/10

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

Monopar Therapeutics (MNPR) presented data from its Phase 3 FoCus trial at AASLD 2026, showing significant disease burden in Wilson disease patients, including cirrhosis, neurologic, and psychiatric symptoms. ALXN1840, Monopar's investigational therapy, demonstrated long-term safety with neutral molybdenum balance and normal uric acid levels over six years.

$MNPRLow

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, August 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative tr

$MNPRMedAI 8/10

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Monopar Therapeutics presented Phase 2 ALXN1840 (tiomolibdate choline) data at EASL 2026 for treatment-experienced Wilson disease patients. In an open-label, multicenter 48-week trial (29 patients; 24 with paired biopsies), histology showed stabilization or improvement in multiple liver measures, with no statistically significant change in hepatic copper. The company also reported significant improvements in UWDRS Part III, CGI, and EQ-5D UK, with generally nonserious Grade 1–2 adverse events.